Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by jts115on Jun 21, 2013 5:20pm
67 Views
Post# 21557007

RE: RE: RE: compensation..

RE: RE: RE: compensation..

I'm sorry man, if management wanted to help the company, they would put up a resolution to liquidate it. Isn't it obvious that a company with a 3 Mln dollar market cap shouldnt be doling out millions of dollars in executive compensation per year? Yeah they sold some assets to petrominerales (below market value), but my constructive suggestion (and my suggestions have all been constructive) would be for the company to lay off all their employees and proceed to sell all their properties.

They only have 2 real assets

1. A minority interest in the guatemala oil properties that they sold to LAR

2. the committment encumbered LLA-27 Block (which according to the latest reserve report and revision, is not even deemed economic to produce from using current metrics)

The company is very weak operationally and should sell these properties to companies that can develop them economically and return the cash to shareholders.

So maybe it is time for the management of the company (and you as well) to take a class in corporate finance 101, maybe then you would understand that just by being there, management continues to destroy value.

Bullboard Posts